• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿沉渣微小RNA反映IgA肾病中的肾小管间质损伤及治疗反应。

Urinary sediment miRNAs reflect tubulointerstitial damage and therapeutic response in IgA nephropathy.

作者信息

Liang Shuang, Cai Guang-Yan, Duan Zhi-Yu, Liu Shu-Wen, Wu Jie, Lv Yang, Hou Kai, Li Zuo-Xiang, Zhang Xue-Guang, Chen Xiang-Mei

机构信息

Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, 28 Fuxing Road, Beijing, 100853, China.

出版信息

BMC Nephrol. 2017 Feb 15;18(1):63. doi: 10.1186/s12882-017-0482-0.

DOI:10.1186/s12882-017-0482-0
PMID:28201996
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5312444/
Abstract

BACKGROUND

Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis worldwide. The clinical spectrum of IgAN varies from minor urinary abnormalities to rapidly progressive renal failure. Evaluation of the disease by repeated renal biopsy is not practical due to its invasive procedure. Urinary sediment miRNAs promise to serve as non-invasive biomarkers to assess kidney injury of IgAN.

METHODS

Fifty two biopsy-proven IgAN patients and twenty five healthy controls were enrolled in the study. Urinary sediment miRNAs were extracted. Expressions of miR-34a, miR-205, miR-21, miR-146a and miR-155 were quantified by real-time quantitative polymerase chain reaction (RT-QPCR). The receiver operating characteristic (ROC) curve was used to investigate the value of the miRNAs for predicting diagnosis of IgAN and evaluating histopathological injury. The patients were treated according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines and followed up. The roles of miRNAs in reflecting therapeutic efficacy and disease progression were analyzed.

RESULTS

  1. The IgAN group had significantly lower urinary miR-34a, miR-205, and miR-155, but higher miR-21 levels than controls. The ROC revealed that urinary miR-34a ≤ 0.047, miR-205 ≤ 0.209, miR-21 ≥ 0.461 and miR-155 ≤ 0.002 could distinguish patients with IgAN from healthy ones. In addition, miR-205 ≤ 0.125 and miR-21 ≥ 0.891 can distinguish IgAN patients with severe tubular atrophy/interstitial fibrosis from those with mild tubular atrophy/interstitial fibrosis. 2. After a mean 15.19 months follow-up, the reduction of proteinuria (g/24 h/year) was positively correlated with baseline urinary miR-21 and inversely correlated with miR-205. The levels of baseline eGFR and miR-205 in the complete remission group were significantly higher than non-complete remission group (p < 0.001; p = 0.018), while proteinuria, miR-21 and miR-146a were lower than non-complete remission group (p = 0.002; p = 0.021; p = 0.009). But multivariate analysis revealed that only baseline eGFR correlated with the remission of IgAN (p = 0.001, OR = 1.042).

CONCLUSIONS

The levels of some urinary sediment miRNAs, especially baseline miR-21 and miR-205, may be used as potential prognostic markers for evaluating the tubulointerstitial damage of IgAN. Furthermore, baseline levels of urinary miRNAs may be predictors of therapeutic efficacy and disease progression.

摘要

背景

免疫球蛋白A肾病(IgAN)是全球最常见的肾小球肾炎。IgAN的临床谱从轻微的尿液异常到快速进展的肾衰竭不等。由于其侵入性操作,通过重复肾活检评估该疾病并不实用。尿沉渣微小RNA有望作为评估IgAN肾损伤的非侵入性生物标志物。

方法

本研究纳入了52例经活检证实的IgAN患者和25例健康对照。提取尿沉渣微小RNA。通过实时定量聚合酶链反应(RT-QPCR)对miR-34a、miR-205、miR-21、miR-146a和miR-155的表达进行定量。采用受试者工作特征(ROC)曲线研究这些微小RNA在预测IgAN诊断和评估组织病理学损伤方面的价值。患者按照肾脏病改善全球预后(KDIGO)指南进行治疗并随访。分析了微小RNA在反映治疗效果和疾病进展中的作用。

结果

  1. IgAN组尿miR-34a、miR-205和miR-155水平显著低于对照组,但miR-21水平高于对照组。ROC曲线显示,尿miR-34a≤0.047、miR-205≤0.209、miR-21≥0.461和miR-155≤0.002可区分IgAN患者与健康人。此外,miR-205≤0.125和miR-21≥0.891可区分严重肾小管萎缩/间质纤维化的IgAN患者与轻度肾小管萎缩/间质纤维化的患者。2. 平均随访15.19个月后,蛋白尿减少量(g/24小时/年)与基线尿miR-21呈正相关,与miR-205呈负相关。完全缓解组的基线eGFR和miR-205水平显著高于未完全缓解组(p<0.001;p=0.018),而蛋白尿、miR-21和miR-146a低于未完全缓解组(p=0.002;p=0.021;p=0.009)。但多因素分析显示,仅基线eGFR与IgAN缓解相关(p=0.001,OR=1.042)。

结论

一些尿沉渣微小RNA的水平,尤其是基线miR-21和miR-205,可能作为评估IgAN肾小管间质损伤的潜在预后标志物。此外,尿微小RNA的基线水平可能是治疗效果和疾病进展的预测指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38d7/5312444/af3806d6b439/12882_2017_482_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38d7/5312444/25af4fa3ae42/12882_2017_482_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38d7/5312444/1d3d13f39b88/12882_2017_482_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38d7/5312444/af3806d6b439/12882_2017_482_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38d7/5312444/25af4fa3ae42/12882_2017_482_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38d7/5312444/1d3d13f39b88/12882_2017_482_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38d7/5312444/af3806d6b439/12882_2017_482_Fig3_HTML.jpg

相似文献

1
Urinary sediment miRNAs reflect tubulointerstitial damage and therapeutic response in IgA nephropathy.尿沉渣微小RNA反映IgA肾病中的肾小管间质损伤及治疗反应。
BMC Nephrol. 2017 Feb 15;18(1):63. doi: 10.1186/s12882-017-0482-0.
2
Urinary exosomal miRNA-451a can be used as a potential noninvasive biomarker for diagnosis, reflecting tubulointerstitial damage and therapeutic response in IgA nephropathy.尿外泌体 miRNA-451a 可用作潜在的无创生物标志物,用于 IgA 肾病的诊断,反映肾小管间质损伤和治疗反应。
Ren Fail. 2024 Dec;46(1):2319326. doi: 10.1080/0886022X.2024.2319326. Epub 2024 Feb 20.
3
Selection of urinary sediment miRNAs as specific biomarkers of IgA nephropathy.选择尿沉渣微小RNA作为IgA肾病的特异性生物标志物。
Sci Rep. 2016 Mar 22;6:23498. doi: 10.1038/srep23498.
4
Urinary miRNA profile for the diagnosis of IgA nephropathy.用于 IgA 肾病诊断的尿 miRNA 谱。
BMC Nephrol. 2019 Mar 4;20(1):77. doi: 10.1186/s12882-019-1267-4.
5
Differential expression of urinary exosomal microRNAs in IgA nephropathy.IgA肾病中尿外泌体微小RNA的差异表达
J Clin Lab Anal. 2018 Feb;32(2). doi: 10.1002/jcla.22226. Epub 2017 Apr 6.
6
Urinary miR-16-5p can be used as a potential marker of endocapillary hypercellularity in IgA nephropathy.尿 miR-16-5p 可作为 IgA 肾病内皮下细胞增多症的潜在标志物。
Sci Rep. 2023 Apr 13;13(1):6048. doi: 10.1038/s41598-023-32910-z.
7
MicroRNAs in IgA nephropathy.IgA 肾病中的 microRNAs。
Ren Fail. 2021 Dec;43(1):1298-1310. doi: 10.1080/0886022X.2021.1977320.
8
Expression of microRNAs in the urinary sediment of patients with IgA nephropathy.IgA 肾病患者尿沉渣中 microRNAs 的表达。
Dis Markers. 2010;28(2):79-86. doi: 10.3233/DMA-2010-0687.
9
Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy.IgA 肾病患者肾活检组织和尿液中 miR-146a 和 miR-155 水平升高。
Dis Markers. 2011;30(4):171-9. doi: 10.3233/DMA-2011-0766.
10
Urinary CXCL1: a novel predictor of IgA nephropathy progression.尿 CXCL1:IgA 肾病进展的新型预测指标。
PLoS One. 2015 Mar 27;10(3):e0119033. doi: 10.1371/journal.pone.0119033. eCollection 2015.

引用本文的文献

1
Development of a multiple urinary biomarker model to predict the tubulointerstitial fibrosis area in patients with primary IgA Nephropathy.开发一种多重尿液生物标志物模型以预测原发性IgA肾病患者的肾小管间质纤维化面积。
BMC Nephrol. 2025 Mar 20;26(1):141. doi: 10.1186/s12882-025-04049-8.
2
IgA Nephropathy: Emerging Mechanisms of Disease.IgA肾病:疾病的新发病机制
Indian J Nephrol. 2024 Jul-Aug;34(4):297-309. doi: 10.25259/ijn_425_23. Epub 2024 Jun 24.
3
Panel miRNAs are potential diagnostic markers for chronic kidney diseases: a systematic review and meta-analysis.

本文引用的文献

1
Time-averaged albumin predicts the long-term prognosis of IgA nephropathy patients who achieved remission.时间平均白蛋白可预测已缓解的IgA肾病患者的长期预后。
J Transl Med. 2014 Jul 10;12:194. doi: 10.1186/1479-5876-12-194.
2
Epithelial-mesenchymal transition and apoptosis of renal tubular epithelial cells are associated with disease progression in patients with IgA nephropathy.肾小管上皮细胞的上皮-间质转化和凋亡与IgA肾病患者的疾病进展相关。
Mol Med Rep. 2014 Jul;10(1):39-44. doi: 10.3892/mmr.2014.2179. Epub 2014 Apr 24.
3
miR-34a regulates mesangial cell proliferation via the PDGFR-β/Ras-MAPK signaling pathway.
面板 miRNA 是慢性肾脏病的潜在诊断标志物:系统评价和荟萃分析。
BMC Nephrol. 2024 Aug 13;25(1):261. doi: 10.1186/s12882-024-03702-y.
4
Blood and urine biomarkers of disease progression in IgA nephropathy.IgA肾病疾病进展的血液和尿液生物标志物
Biomark Res. 2024 Jul 29;12(1):72. doi: 10.1186/s40364-024-00619-4.
5
Integrated miRNA-mRNA Analysis Reveals Critical miRNAs and Targets in Diet-Induced Obesity-Related Glomerulopathy.整合 miRNA-mRNA 分析揭示了饮食诱导肥胖相关性肾小球病中的关键 miRNA 和靶标。
Int J Mol Sci. 2024 Jun 11;25(12):6437. doi: 10.3390/ijms25126437.
6
Urinary miR-185-5p is a biomarker of renal tubulointerstitial fibrosis in IgA nephropathy.尿 miR-185-5p 是 IgA 肾病肾小管间质纤维化的生物标志物。
Front Immunol. 2024 Feb 15;15:1326026. doi: 10.3389/fimmu.2024.1326026. eCollection 2024.
7
Urinary miR-16-5p can be used as a potential marker of endocapillary hypercellularity in IgA nephropathy.尿 miR-16-5p 可作为 IgA 肾病内皮下细胞增多症的潜在标志物。
Sci Rep. 2023 Apr 13;13(1):6048. doi: 10.1038/s41598-023-32910-z.
8
Blood TGF-β1 and miRNA-21-5p levels predict renal fibrosis and outcome in IgA nephropathy.血清 TGF-β1 和 miRNA-21-5p 水平可预测 IgA 肾病的肾纤维化和转归。
Int Urol Nephrol. 2023 Jun;55(6):1557-1564. doi: 10.1007/s11255-023-03464-w. Epub 2023 Jan 17.
9
Noncoding RNAs associated with IgA nephropathy.与 IgA 肾病相关的非编码 RNA。
J Nephrol. 2023 Apr;36(3):911-923. doi: 10.1007/s40620-022-01498-4. Epub 2022 Dec 10.
10
MicroRNAs in kidney injury and disease.微小 RNA 与肾脏损伤和疾病
Nat Rev Nephrol. 2022 Oct;18(10):643-662. doi: 10.1038/s41581-022-00608-6. Epub 2022 Aug 16.
微小RNA-34a通过血小板衍生生长因子受体-β/ Ras-丝裂原活化蛋白激酶信号通路调节系膜细胞增殖。
Cell Mol Life Sci. 2014 Oct;71(20):4027-42. doi: 10.1007/s00018-014-1599-y. Epub 2014 Mar 18.
4
Increased circulating miR-21 levels are associated with kidney fibrosis.循环 miR-21 水平的升高与肾脏纤维化有关。
PLoS One. 2013;8(2):e58014. doi: 10.1371/journal.pone.0058014. Epub 2013 Feb 28.
5
Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice.miR-21 通过调节 MMP-9 和 TIMP1 对 kk-ay 糖尿病肾病小鼠肾纤维化的影响。
Cell Biochem Biophys. 2013 Nov;67(2):537-46. doi: 10.1007/s12013-013-9539-2.
6
miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes.miR-21 是 2 型糖尿病小鼠模型肾损伤的关键治疗靶点。
Diabetologia. 2013 Mar;56(3):663-74. doi: 10.1007/s00125-012-2804-x. Epub 2013 Jan 5.
7
MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways.MicroRNA-21 通过沉默代谢途径促进肾脏纤维化。
Sci Transl Med. 2012 Feb 15;4(121):121ra18. doi: 10.1126/scitranslmed.3003205.
8
Clinical features and outcomes of IgA nephropathy with nephrotic syndrome.IgA 肾病伴肾病综合征的临床特征和结局。
Clin J Am Soc Nephrol. 2012 Mar;7(3):427-36. doi: 10.2215/CJN.04820511. Epub 2012 Jan 5.
9
MicroRNA expression data reveals a signature of kidney damage following ischemia reperfusion injury.miRNA 表达数据揭示了缺血再灌注损伤后肾脏损伤的特征。
PLoS One. 2011;6(8):e23011. doi: 10.1371/journal.pone.0023011. Epub 2011 Aug 15.
10
Smad3-mediated upregulation of miR-21 promotes renal fibrosis.Smad3 介导的 miR-21 上调促进肾纤维化。
J Am Soc Nephrol. 2011 Sep;22(9):1668-81. doi: 10.1681/ASN.2010111168. Epub 2011 Aug 18.